Los Angeles Capital Management LLC Raises Holdings in DexCom, Inc. (NASDAQ:DXCM)

Los Angeles Capital Management LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 287.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 313,796 shares of the medical device company's stock after acquiring an additional 232,705 shares during the quarter. Los Angeles Capital Management LLC owned about 0.08% of DexCom worth $21,429,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Golden State Wealth Management LLC raised its position in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of DexCom by 29.3% in the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares during the last quarter. Private Trust Co. NA raised its position in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after purchasing an additional 335 shares during the last quarter. Dynamic Advisor Solutions LLC raised its position in shares of DexCom by 34.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after purchasing an additional 1,333 shares during the last quarter. Finally, Stonebridge Financial Group LLC raised its position in DexCom by 944.5% in the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company's stock worth $220,000 after buying an additional 2,909 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total transaction of $228,607.50. Following the sale, the director owned 56,621 shares in the company, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $85.06, for a total value of $124,697.96. Following the sale, the executive vice president owned 108,155 shares in the company, valued at $9,199,664.30. The trade was a 1.34% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of DXCM traded up $0.35 during mid-day trading on Thursday, hitting $86.78. 637,641 shares of the stock were exchanged, compared to its average volume of 3,850,256. The company has a market cap of $34.03 billion, a PE ratio of 64.76, a price-to-earnings-growth ratio of 1.82 and a beta of 1.44. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $112.55. The firm has a 50-day moving average of $84.49 and a two-hundred day moving average of $80.30. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period last year, the company earned $0.32 earnings per share. The firm's revenue was up 12.5% on a year-over-year basis. On average, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on DXCM. Wall Street Zen raised DexCom from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Citigroup reiterated a "buy" rating and set a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Barclays boosted their price objective on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research note on Monday, May 5th. Piper Sandler cut their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Finally, Robert W. Baird cut their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $99.60.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.